Portal Hypertension – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Portal Hypertension – Pipeline Review, H2 2016’, provides an overview of the Portal Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Portal Hypertension

The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects

The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Portal Hypertension

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Portal Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Conatus Pharmaceuticals Inc.

Cumberland Pharmaceuticals, Inc.

Galectin Therapeutics, Inc.

Genextra S.p.a.

LinXis B.V.

Mezzion Pharma Co. Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Portal Hypertension Overview 6

Therapeutics Development 7

Pipeline Products for Portal Hypertension - Overview 7

Portal Hypertension - Therapeutics under Development by Companies 8

Portal Hypertension - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Portal Hypertension - Products under Development by Companies 11

Portal Hypertension - Companies Involved in Therapeutics Development 12

Conatus Pharmaceuticals Inc. 12

Cumberland Pharmaceuticals, Inc. 13

Galectin Therapeutics, Inc. 14

Genextra S.p.a. 15

LinXis B.V. 16

Mezzion Pharma Co. Ltd. 17

Portal Hypertension - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

emricasan - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

GRMD-02 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ifetroban sodium - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

LIN-003 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

obeticholic acid - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

udenafil - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Portal Hypertension - Dormant Projects 60

Portal Hypertension - Discontinued Products 61

Portal Hypertension - Product Development Milestones 62

Featured News & Press Releases 62

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 62

ep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis 62

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 64

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 65

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 65

Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting 66

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Tables

List of Tables

Number of Products under Development for Portal Hypertension, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Portal Hypertension – Pipeline by Conatus Pharmaceuticals Inc., H2 2016 12

Portal Hypertension – Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016 13

Portal Hypertension – Pipeline by Galectin Therapeutics, Inc., H2 2016 14

Portal Hypertension – Pipeline by Genextra S.p.a., H2 2016 15

Portal Hypertension – Pipeline by LinXis B.V., H2 2016 16

Portal Hypertension – Pipeline by Mezzion Pharma Co. Ltd., H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Portal Hypertension – Dormant Projects, H2 2016 60

Portal Hypertension – Discontinued Products, H2 2016 61

List of Figures

List of Figures

Number of Products under Development for Portal Hypertension, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Top 10 Targets, H2 2016 19

Number of Products by Stage and Top 10 Targets, H2 2016 19

Number of Products by Top 10 Mechanism of Actions, H2 2016 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports